Role of surgical resection for patients with limited disease-small cell lung cancer

Takenaka, Tomoyoshi; Takenoyama, Mitsuhiro; Inamasu, Eiko; Yoshida, Tsukihisa; Toyokawa, Gouji; Nosaki, Kaname; Hirai, Fumihiko; Yamaguchi, Masafumi; Shimokawa, Mototsugu; Seto, Takashi; Ichinose, Yukito

doi:10.1016/j.lungcan.2015.01.010

Cited by 63 publications

(63 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Significant difference benefiting youth was only achieved in patients who underwent non-surgical treatment. For patients with resectable SCLC, outcomes after surgery were comparable to those with resectable NSCLC [34] and even better than SCLC patients who didn't receive surgery [35]. Our study might demonstrated that the benefit of surgery didn't exist in all ages.…”

Section: Discussionmentioning

confidence: 69%

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III

et al. 2017

View full text Add to dashboard Cite

It has been reported that younger patients with non-small cell lung cancer (NSCLC) tend to have a better prognosis. Yet, few studies have focused on the clinicopathological characteristics and prognosis of young small cell lung cancer (SCLC), especially for patients with age < 50. In our study, we used Surveillance, Epidemiology, and End Results (SEER) population-based data and identified 16503 patients with SCLC including 711 patients aged < 50, 3338 patients aged 50–59, 5937 patients aged 60–69, 4649 patients aged 70–79 and 1868 patients aged ≥ 80 between 2010 and 2013. The Kaplan-Meier methods was used to develop the survival curve, and the results showed that the SCLC patients with aged < 50 tended to a better over survival (OS) and cancer specific survival (CSS) (all, P < 0.001). In addition, Cox regression model was used to analyze survival prognosis factors and perform subgroup analysis. The results showed that age was an independent prognostic factor for CSS (P < 0.001). Importantly, we found that for the patients with AJCC stage III subgroup, the age < 50 had apparent CSS benefit compared with any other age group (all, P < 0.01). Interestingly, for the patients with no surgery, radiation and no radiation subgroup, the age < 50 had no apparent CSS benefit only compared with age 50–59 (all, P > 0.05). In conclusion, our study demonstrated that the SCLC patients with aged < 50 tended had a better survival benefit, especially for patients with AJCC stage III.

show abstract

Section: Discussionmentioning

confidence: 69%

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In the 1970s, two significant reports demonstrating poor survival in patients with SCLC after surgery compared to nonsurgical treatment made SCLC the exception for surgery . After some decades, several authors began to report the role of surgery as primary treatment in a small number of SCLC patients . In 2005, the Japan Clinical Oncology Lung Cancer Study Group reported three‐year survival of 68% for stage I disease after surgery and adjuvant chemotherapy …”

Section: Introductionmentioning

confidence: 99%

“…9,10 After some decades, several authors began to report the role of surgery as primary treatment in a small number of SCLC patients. [11][12][13] In 2005, the Japan Clinical Oncology Lung Cancer Study Group reported three-year survival of 68% for stage I disease after surgery and adjuvant chemotherapy. 14 The recently updated National Comprehensive Cancer Network (NCCN) guidelines recommend lobectomy and mediastinal lymph node sampling or dissection and adjuvant therapy according to pathologic N status.…”

Section: Introductionmentioning

confidence: 99%

Effect of histological subtype and treatment modalities on T1–2 N0–1 small cell lung cancer: A population‐based study

et al. 2019

View full text Add to dashboard Cite

Background Combined small cell lung cancer (C‐SCLC) is rare and its clinical features, appropriate treatment, and prognosis are poorly understood. Reports conflict over the prognosis of C‐SCLCs compared to pure small cell lung cancer. Methods The records of patients diagnosed with primary SCLC from 1988 to 2014 were extracted from the Surveillance, Epidemiology, and End Results database. The general features of C‐SCLCs were compared to those of SCLCs. T1–2 N0–1 data was extracted and the effects of the histological subtype, treatment modality, and other prognostic factors on lung cancer‐specific survival (CSS) was analyzed in a 3:1 matched dataset. Analysis was performed using the 8th edition tumor node metastasis staging system and previous staging systems adjunctively. Results C‐SCLCs comprised 1.5% of all SCLCs (1486/98 667); 184 cases of C‐SCLCs and 2681 cases of non‐combined SCLCs (NC‐SCLCs) were included in this study. C‐SCLCs were more likely to be of a higher grade and to occur in the upper lobe than NC‐SCLCs. Before matching, C‐SCLCs showed better CSS (hazard ratio 0.69; P < 0.001). However, stratified Cox proportional hazards analysis in the matched dataset revealed that only treatment modality and age at diagnosis were associated with CSS; the histological subtype had no effect on survival. Of all treatment modalities, surgery with chemoradiation showed the best CSS in T1–2 N0–1 SCLC. Conclusion In early SCLC, surgery with chemoradiation shows the best CSS. C‐SCLC patients might benefit more from multimodal treatments, including surgery, than SCLC patients.

show abstract

“…However, several retrospective analyses suggest improved os with surgery in T1/2aN0 disease [36][37][38] . Guidelines recommend that surgical resection of clinical stage i sclc remain reserved for medically fit patients, only after confirmation with invasive mediastinal staging and extrathoracic imaging 1,2,39 .…”

mentioning

confidence: 99%

Management of Small-Cell Lung Cancer with Radiotherapy—A Pan-Canadian Survey of Radiation Oncologists

et al. 2016

View full text Add to dashboard Cite

show abstract

Role of surgical resection for patients with limited disease-small cell lung cancer

Cited by 63 publications

References 23 publications

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III

Effect of histological subtype and treatment modalities on T1–2 N0–1 small cell lung cancer: A population‐based study

Management of Small-Cell Lung Cancer with Radiotherapy—A Pan-Canadian Survey of Radiation Oncologists

Contact Info

Product

Resources

About